LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

<
<<
Previous
Page 1 of 535
Next
>>
>
1 to 25 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Seliciclib	3.33	uM	LJP5	3	J02	72	hr	1657	4633	5529	0.8379	0.8065
BT-20	AT-7519	0.12	uM	LJP6	2	K05	72	hr	1657	4398	5360	0.8205	0.7794
BT-20	Seliciclib	0.37	uM	LJP5	1	J04	72	hr	1657	5298	5624	0.9420	0.9333
BT-20	Seliciclib	3.33	uM	LJP5	2	J02	72	hr	1657	4469	5610	0.7965	0.7573
BT-20	AT-7519	0.04	uM	LJP6	1	K06	72	hr	1657	5160	5244	0.9838	0.9805
BT-20	AT-7519	0.12	uM	LJP6	1	K05	72	hr	1657	4339	5244	0.8273	0.7843
BT-20	Seliciclib	0.04	uM	LJP5	3	J06	72	hr	1657	5764	5529	1.0424	1.0484
BT-20	Seliciclib	0.12	uM	LJP5	3	J05	72	hr	1657	5641	5529	1.0202	1.0231
BT-20	Seliciclib	1.11	uM	LJP5	1	J03	72	hr	1657	4597	5624	0.8174	0.7838
BT-20	Seliciclib	3.33	uM	LJP5	1	J02	72	hr	1657	4540	5624	0.8072	0.7712
BT-20	Seliciclib	10	uM	LJP5	2	J01	72	hr	1657	2227	5610	0.3969	0.1827
BT-20	Seliciclib	10	uM	LJP5	3	J01	72	hr	1657	1957	5529	0.3539	0.1002
BT-20	AT-7519	0.04	uM	LJP6	2	K06	72	hr	1657	5258	5360	0.9809	0.9774
BT-20	AT-7519	0.04	uM	LJP6	3	K06	72	hr	1657	4928	5546	0.8886	0.8689
BT-20	Seliciclib	0.04	uM	LJP5	1	J06	72	hr	1657	5649	5624	1.0044	1.0050
BT-20	Seliciclib	0.04	uM	LJP5	2	J06	72	hr	1657	5742	5610	1.0234	1.0265
BT-20	Seliciclib	0.12	uM	LJP5	1	J05	72	hr	1657	5349	5624	0.9511	0.9439
BT-20	Seliciclib	0.12	uM	LJP5	2	J05	72	hr	1657	5765	5610	1.0275	1.0311
BT-20	Seliciclib	0.37	uM	LJP5	2	J04	72	hr	1657	5240	5610	0.9339	0.9238
BT-20	Seliciclib	0.37	uM	LJP5	3	J04	72	hr	1657	5100	5529	0.9223	0.9091
BT-20	Seliciclib	1.11	uM	LJP5	2	J03	72	hr	1657	4956	5610	0.8833	0.8638
BT-20	Seliciclib	1.11	uM	LJP5	3	J03	72	hr	1657	4738	5529	0.8569	0.8299
BT-20	Seliciclib	10	uM	LJP5	1	J01	72	hr	1657	2369	5624	0.4212	0.2245
BT-20	AT-7519	0.37	uM	LJP6	1	K04	72	hr	1657	1815	5244	0.3461	0.0561
BT-20	AT-7519	0.12	uM	LJP6	3	K05	72	hr	1657	4202	5546	0.7577	0.7055

<
<<
Previous
Page 1 of 535
Next
>>
>
1 to 25 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)